120 related articles for article (PubMed ID: 11809983)
1. Practice, efficacy and cost of staging suspected non-small cell lung cancer: a retrospective study in two Dutch hospitals.
Herder GJ; Verboom P; Smit EF; van Velthoven PC; van den Bergh JH; Colder CD; van Mansom I; van Mourik JC; Postmus PE; Teule GJ; Hoekstra OS
Thorax; 2002 Jan; 57(1):11-4. PubMed ID: 11809983
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of FDG-PET in staging non-small cell lung cancer: the PLUS study.
Verboom P; van Tinteren H; Hoekstra OS; Smit EF; van den Bergh JH; Schreurs AJ; Stallaert RA; van Velthoven PC; Comans EF; Diepenhorst FW; van Mourik JC; Postmus PE; Boers M; Grijseels EW; Teule GJ; Uyl-de Groot CA;
Eur J Nucl Med Mol Imaging; 2003 Nov; 30(11):1444-9. PubMed ID: 14579081
[TBL] [Abstract][Full Text] [Related]
3. Staging of non-small-cell lung cancer and application of FDG-PET. A cost modeling approach.
Verboom P; Herder GJ; Hoekstra OS; Smit EF; van den Bergh JH; van Velthoven PC; Grijseels EW
Int J Technol Assess Health Care; 2002; 18(3):576-85. PubMed ID: 12391950
[TBL] [Abstract][Full Text] [Related]
4. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
[TBL] [Abstract][Full Text] [Related]
5. [PET with (18)F-fluorodeoxyglucose for staging of non-small cell lung cancer].
Weber WA; Dietlein M; Hellwig D; Kirsch CM; Schicha H; Schwaiger M
Nuklearmedizin; 2003 Aug; 42(4):135-44. PubMed ID: 12937692
[TBL] [Abstract][Full Text] [Related]
6. Traditional versus up-front [18F] fluorodeoxyglucose-positron emission tomography staging of non-small-cell lung cancer: a Dutch cooperative randomized study.
Herder GJ; Kramer H; Hoekstra OS; Smit EF; Pruim J; van Tinteren H; Comans EF; Verboom P; Uyl-de Groot CA; Welling A; Paul MA; Boers M; Postmus PE; Teule GJ; Groen HJ;
J Clin Oncol; 2006 Apr; 24(12):1800-6. PubMed ID: 16567772
[TBL] [Abstract][Full Text] [Related]
7. Clinical impact of (18)F fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer: a prospective study.
Kalff V; Hicks RJ; MacManus MP; Binns DS; McKenzie AF; Ware RE; Hogg A; Ball DL
J Clin Oncol; 2001 Jan; 19(1):111-8. PubMed ID: 11134203
[TBL] [Abstract][Full Text] [Related]
8. Positron emission tomography with selected mediastinoscopy compared to routine mediastinoscopy offers cost and clinical outcome benefits for pre-operative staging of non-small cell lung cancer.
Yap KK; Yap KS; Byrne AJ; Berlangieri SU; Poon A; Mitchell P; Knight SR; Clarke PC; Harris A; Tauro A; Rowe CC; Scott AM
Eur J Nucl Med Mol Imaging; 2005 Sep; 32(9):1033-40. PubMed ID: 15875178
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial.
van Tinteren H; Hoekstra OS; Smit EF; van den Bergh JH; Schreurs AJ; Stallaert RA; van Velthoven PC; Comans EF; Diepenhorst FW; Verboom P; van Mourik JC; Postmus PE; Boers M; Teule GJ
Lancet; 2002 Apr; 359(9315):1388-93. PubMed ID: 11978336
[TBL] [Abstract][Full Text] [Related]
10. Is FDG PET/CT cost-effective for pre-operation staging of potentially operative non-small cell lung cancer? - From Chinese healthcare system perspective.
Wang YT; Huang G
Eur J Radiol; 2012 Aug; 81(8):e903-9. PubMed ID: 22698711
[TBL] [Abstract][Full Text] [Related]
11. [Impact of positron emission tomography on clinical management of potentially resectable non-small-cell lung cancer: a French prospective multicenter study].
Margery J; Milleron B; Vaylet F; Grahek D; Lebeau B; Mangiapan G; Bonardel G; de Labriolle-Vaylet C; Meignan M; Carette MF; Talbot JN; Housset B
Rev Pneumol Clin; 2010 Oct; 66(5):313-20. PubMed ID: 21087727
[TBL] [Abstract][Full Text] [Related]
12. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis.
Senthi S; Lagerwaard FJ; Haasbeek CJ; Slotman BJ; Senan S
Lancet Oncol; 2012 Aug; 13(8):802-9. PubMed ID: 22727222
[TBL] [Abstract][Full Text] [Related]
13. False-negative rate after positron emission tomography/computer tomography scan for mediastinal staging in cI stage non-small-cell lung cancer.
Gómez-Caro A; Boada M; Cabañas M; Sanchez M; Arguis P; Lomeña F; Ramirez J; Molins L
Eur J Cardiothorac Surg; 2012 Jul; 42(1):93-100; discussion 100. PubMed ID: 22290911
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of hybrid PET/CT for staging of non-small cell lung cancer.
Schreyögg J; Weller J; Stargardt T; Herrmann K; Bluemel C; Dechow T; Glatting G; Krause BJ; Mottaghy F; Reske SN; Buck AK
J Nucl Med; 2010 Nov; 51(11):1668-75. PubMed ID: 21051648
[TBL] [Abstract][Full Text] [Related]
15. Cost-benefit of minimally invasive staging of non-small cell lung cancer: a decision tree sensitivity analysis.
Steinfort DP; Liew D; Conron M; Hutchinson AF; Irving LB
J Thorac Oncol; 2010 Oct; 5(10):1564-70. PubMed ID: 20871261
[TBL] [Abstract][Full Text] [Related]
16. 7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung cancer: Results of a phase 2 clinical trial.
Sun B; Brooks ED; Komaki RU; Liao Z; Jeter MD; McAleer MF; Allen PK; Balter PA; Welsh JD; O'Reilly MS; Gomez D; Hahn SM; Roth JA; Mehran RJ; Heymach JV; Chang JY
Cancer; 2017 Aug; 123(16):3031-3039. PubMed ID: 28346656
[TBL] [Abstract][Full Text] [Related]
17. Positron emission tomography-computed tomography compared with invasive mediastinal staging in non-small cell lung cancer: results of mediastinal staging in the early lung positron emission tomography trial.
Darling GE; Maziak DE; Inculet RI; Gulenchyn KY; Driedger AA; Ung YC; Gu CS; Kuruvilla MS; Cline KJ; Julian JA; Evans WK; Levine MN
J Thorac Oncol; 2011 Aug; 6(8):1367-72. PubMed ID: 21587082
[TBL] [Abstract][Full Text] [Related]
18. Preoperative intrathoracic lymph node staging in patients with non-small-cell lung cancer: accuracy of integrated positron emission tomography and computed tomography.
Billé A; Pelosi E; Skanjeti A; Arena V; Errico L; Borasio P; Mancini M; Ardissone F
Eur J Cardiothorac Surg; 2009 Sep; 36(3):440-5. PubMed ID: 19464906
[TBL] [Abstract][Full Text] [Related]
19. Cost-minimization analysis of alternative diagnostic approaches in a modeled patient with non-small cell lung cancer and subcarinal lymphadenopathy.
Harewood GC; Wiersema MJ; Edell ES; Liebow M
Mayo Clin Proc; 2002 Feb; 77(2):155-64. PubMed ID: 11838649
[TBL] [Abstract][Full Text] [Related]
20. Impact of 18F-FDG PET/CT in the treatment of patients with non-small cell lung cancer.
Taus Á; Aguiló R; Curull V; Suárez-Piñera M; Rodríguez-Fuster A; Rodríguez de Dios N; Pijuan L; Zuccarino F; Vollmer I; Sánchez-Font A; Belda-Sanchis J; Arriola E
Arch Bronconeumol; 2014 Mar; 50(3):99-104. PubMed ID: 24360985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
